4M Therapeutics Presented Novel Preclinical Data at SOBP Annual Meeting 2024 Demonstrating Potent Effects of Inhibitors of GSK3β for the Treatment of Bipolar Disorder
May 13 2024 - 3:02PM
Business Wire
- GSK3 inhibitors showed successful CNS target engagement and
efficacy comparable to lithium at significantly lower doses in
models of bipolar disorder
4M Therapeutics Inc., an early-stage biotechnology company
developing treatments for neuropsychiatric and neurodegenerative
conditions, today announced the presentation of a poster at the
Society of Biological Psychiatry (SOBP) Annual Meeting, that
occurred from May 9-11, 2024, in Austin, Texas. The poster, titled
“The Effects of Novel Small Molecules in a Preclinical Model of
Positive Affective State,” was presented on May 11, 2024.
“Our presentation underscored the capability of our novel small
molecules to selectively target GSK3β and demonstrate efficacy for
the treatment of bipolar disorder and acute mania,” said Dr. Pablo
Lapuerta, Chief Executive Officer and Co-Founder of 4M
Therapeutics. “We continue to accelerate the development of
much-needed therapeutic options that have the potential to
significantly improve upon the safety and efficacy of the standard
of care for patients with neuropsychiatric conditions. We remain on
track to initiate a Phase 1 clinical trial for our lead
investigational compound in 2025.”
The poster examined the effects of 4M Therapeutics’ glycogen
synthase kinase 3 beta (GSK3β) inhibitors, 4MT-A and 4MT-B, on
amphetamine (AMP)-induced positive appetitive ultrasonic
vocalizations (USVs), a validated model of positive affective
state. Marked increases in USVs when treated with AMP were
attenuated by lithium, and equal or greater reduction in USVs was
observed when treated with 4MT-A and 4MT-B at 1/500th to 1/1000th
the concentration of lithium. Similar patterns were observed across
USV categories and treatment groups in both the first and second
hour after AMP dosing. In addition, supporting data showed target
engagement for 4MT-A through the reduction of pCRMP2 in vitro in
excitatory cortical neurons and in vivo in rat brain. These
statistically significant reductions in pCRMP2 demonstrated GSK3β
inhibition affecting a key biomarker.
About 4M Therapeutics Inc.
4M Therapeutics Inc. (4MTx) is advancing treatments for
neuropsychiatric and neurodegenerative conditions. The Company
focuses on targets for a wide array of disorders and indications.
4MTx applies unique insights from its living human brain cell
platform, which was developed through a collaboration between
Harvard, MIT, and the University of Washington to identify and
design more effective and safer therapeutics. The Company’s
pipeline includes potential breakthrough treatments for bipolar
mania, agitation in Alzheimer’s disease, neurodegeneration, and
other CNS disorders. For more information, visit www.4mtx.net.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240513905497/en/
For investor and media inquiries, please contact:
Kimberly Lee, DO Chief Business Officer ir@4mtx.net